GERN Geron Corporation

1.36
-0.04  -3%
Previous Close 1.4
Open 1.4
Price To Book 1.79
Market Cap 271,697,562
Shares 199,777,619
Volume 1,265,703
Short Ratio
Av. Daily Volume 1,384,119
Stock charts supplied by TradingView

NewsSee all news

  1. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 98,000 shares of Geron common stock as inducements to two newly-hired employees in connection

  2. Geron Announces 2019 Accomplishments and Key Development Priorities for 2020

    Geron Corporation (NASDAQ:GERN), a late-stage clinical development biopharmaceutical company, today announced 2019 accomplishments and key development priorities for 2020. The Company is currently enrolling patients in

  3. Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 100,000 shares of Geron common stock as an inducement to a newly-hired employee in connection

  4. Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis

    Geron Corporation (NASDAQ:GERN) today announced that the Company has conducted an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the IMbark Phase 2 clinical trial of

  5. Geron Reports Two Poster Presentations at American Society of Hematology Annual Meeting

    Geron Corporation (NASDAQ:GERN) today announced that two posters related to imetelstat, the Company's first-in-class telomerase inhibitor, were presented at the 61st American Society of Hematology (ASH) Annual Meeting

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 commencement of dosing announced October 10, 2019 with data due mid-2022.
Imetelstat - IMerge Study
Myelodysplastic syndromes
Janssen noted September 27, 2018 not to continue collaboration. Decision on future development due by 3Q 2019.
Imetelstat - IMbarkStudy
Myelofibrosis

Latest News

  1. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 98,000 shares of Geron common stock as inducements to two newly-hired employees in connection

  2. Geron Announces 2019 Accomplishments and Key Development Priorities for 2020

    Geron Corporation (NASDAQ:GERN), a late-stage clinical development biopharmaceutical company, today announced 2019 accomplishments and key development priorities for 2020. The Company is currently enrolling patients in

  3. Geron Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

    Geron Corporation (NASDAQ:GERN) today reported that it has granted a non-statutory stock option to purchase an aggregate of 100,000 shares of Geron common stock as an inducement to a newly-hired employee in connection

  4. Geron Conducts End of Phase 2 Meeting for Imetelstat in Relapsed/Refractory Myelofibrosis

    Geron Corporation (NASDAQ:GERN) today announced that the Company has conducted an End of Phase 2 meeting with the U.S. Food and Drug Administration (FDA) to discuss the results of the IMbark Phase 2 clinical trial of

  5. Geron Reports Two Poster Presentations at American Society of Hematology Annual Meeting

    Geron Corporation (NASDAQ:GERN) today announced that two posters related to imetelstat, the Company's first-in-class telomerase inhibitor, were presented at the 61st American Society of Hematology (ASH) Annual Meeting

  6. Geron Announces Appointment of New Executive to Focus on Corporate Strategy

    Geron Corporation (NASDAQ:GERN) today announced the appointment of Anil Kapur as Executive Vice President, Corporate Strategy and Chief Commercial Officer. With this appointment, all functions of a fully-integrated,

  7. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Nov. 21, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 150,000 shares of Geron common stock as

  8. Geron Corporation Reports Third Quarter 2019 Financial Results and Recent Events

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported financial results for the third quarter and year-to-date as of September 30, 2019 as well as recent events. The

  9. Geron Announces Two Poster Presentations at Upcoming American Society of Hematology Annual Meeting

    MENLO PARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that two abstracts related to imetelstat, the Company's first-in-class telomerase inhibitor, have been accepted for

  10. Geron to Announce Third Quarter Financial Results on November 6, 2019

    MENLO PARK, Calif., Oct. 31, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that it will release its third quarter 2019 financial results after the market closes on Wednesday, November 6, 2019

  11. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Oct. 17, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 200,000 shares of Geron common stock as

  12. Geron Announces First Patient Dosed in IMerge Phase 3 Clinical Trial in Lower Risk Myelodysplastic Syndromes

    MENLO PARK, Calif., Oct. 10, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that the first patient has been dosed in the IMerge Phase 3 clinical trial to evaluate imetelstat, a first-in-class

  13. Geron Announces Fast Track Designation Granted to Imetelstat for Relapsed/Refractory Myelofibrosis

    MENLO PARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that the United States Food and Drug Administration (FDA) has granted Fast Track designation to imetelstat for the

  14. Geron to Present at 2019 Cantor Global Healthcare Conference

    MENLO PARK, Calif., Sept. 26, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today announced that John A. Scarlett, M.D., Chairman and Chief Executive Officer, is scheduled to present a company overview at

  15. Geron Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

    MENLO PARK, Calif., Aug. 22, 2019 (GLOBE NEWSWIRE) -- Geron Corporation (NASDAQ:GERN) today reported that it has granted non-statutory stock options to purchase an aggregate of 240,000 shares of Geron common stock as